Hemostemix Inc. (CVE:HEM – Get Free Report) fell 22.9% on Friday . The stock traded as low as C$0.18 and last traded at C$0.19. 504,239 shares changed hands during trading, a decline of 5% from the average session volume of 530,580 shares. The stock had previously closed at C$0.24.
Hemostemix Trading Up 5.4 %
The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The firm has a market capitalization of C$28.42 million, a P/E ratio of -5.69 and a beta of 0.20. The firm has a fifty day simple moving average of C$0.19 and a two-hundred day simple moving average of C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- What Are Dividend Achievers? An Introduction
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- What Are Dividend Contenders? Investing in Dividend Contenders
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- How to Short Nasdaq: An Easy-to-Follow Guide
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
